Kindred Biosciences, Inc.
DelistedCIK 1561743fmd_10MNHDH71AHBMZ2VRDWEFT975HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2012 to Jun 30, 2021, 35 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 2 | 4 | 42 |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 1 | 5 |
| Gross profit | – | – | – | 0 | 0 | 2 | 4 | 38 |
| Research and development | 3 | 19 | 19 | 14 | 18 | 26 | 28 | 31 |
| Total operating expenses | 4 | 27 | 27 | 23 | 32 | 53 | – | – |
| Operating income | (4) | (27) | (27) | (23) | (32) | (51) | (63) | (20) |
| Interest and investment income | – | 0 | 0 | 0 | 1 | 2 | 1 | – |
| Other non-operating income (expense) | – | – | – | – | – | 2 | 1 | (2) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (4) | (27) | (27) | (22) | (31) | (50) | (61) | (22) |